What You Need to Know About a New Peanut Allergy Treatment

By Kelly Glass: For More Info, Go Here…

If approved by the FDA, the new treatment might allow peanut-allergic kids to eat small amounts of peanuts, but at what risk?

The U.S. Food and Drug Administration expert panel recommended the approval of the first drug designed to treat peanut allergies in children by reducing the allergic reaction. The drug, called Palforzia by Aimmune Therapeutics, would be the first of its kind approved to prevent or lessen the severity of life-threatening peanut allergy reactions in children.

Palforzia is an oral immunotherapy drug in a capsule form. The capsule contains a pharmaceutical-grade dose of the peanut protein meant to gradually and safely desensitize children to potentially life-threatening peanut allergy reactions.

It’s delivered as a daily dose of peanut protein, which increases over time, for children ages 4–17. According to a study published last year in the New England Journal of Medicine, about two-thirds of the peanut-allergic children in a clinical trial who participated in the treatment for about a year were able to eat at least two peanuts with no or mild symptoms.

In this trial, children and teens who were highly allergic to peanut and treated with the drug could ingest higher doses of peanut protein without symptoms or with lower severity symptoms during peanut exposure at the exit food challenge than the children in the placebo group. It’s important to note that during treatment, however, more than 9 percent of patients taking the peanut-allergy treatment drug reported severe allergic reactions — more than twice the number in the placebo group.

Leave a Reply